KRAS and colorectal cancer: To investigate this, we utilized an isogenic set of KRAS‐mutant (mt) HCT116 (constitutively active KRAS) and genetically corrected WT HKh‐2 and HKe‐3 colorectal cancer lines (Shirasawa et al., 1993; Van Schaeybroeck et al., 2014), which exhibited similar growth rates (Fig. S2A).